Hiroki Konishi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7317808/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Doxorubicin alters the disposition of phenytoin by reducing its metabolic elimination and binding affinity to serum albumin in rats. Journal of Pharmacy and Pharmacology, 2022, 74, 200-207.	2.4	0
2	Effects of concurrent and staggered dosing of semi-solid enteral nutrients on pharmacokinetic behavior of antiepileptic drugs after oral administration in rats. PLoS ONE, 2021, 16, e0259400.	2.5	2
3	Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells. Anticancer Research, 2021, 41, 6105-6112.	1.1	3
4	Pharmacokinetic interference of doxorubicin with tolbutamide due to reduced metabolic clearance with increased serum unbound fraction in rats. Biopharmaceutics and Drug Disposition, 2019, 40, 225-233.	1.9	1
5	Enhanced anti-cancer activity by menthol in HepC2 cells exposed to paclitaxel and vincristine: possible involvement of CYP3A4 downregulation. Drug Metabolism and Personalized Therapy, 2019, 34, .	0.6	9
6	Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam. Xenobiotica, 2019, 49, 1470-1477.	1.1	4
7	Prevention of Doxorubicin-Induced Renal Toxicity by Theanine in Rats. Pharmacology, 2018, 101, 219-224.	2.2	27
8	Altered tolbutamide pharmacokinetics by a decrease in hepatic expression of CYP2C6/11 in rats pretreated with 5-fluorouracil. Xenobiotica, 2018, 48, 53-59.	1.1	7
9	Pharmacokinetics and metabolic elimination of tolbutamide in female rats: Comparison with male rats. Biopharmaceutics and Drug Disposition, 2018, 39, 321-327.	1.9	8
10	Enhanced Understanding of the Levels of Palliative Care in Pharmacy Students Through Participating in Hospitals. Journal of Pharmacy Practice, 2017, 30, 313-317.	1.0	2
11	Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1. Drug Metabolism Letters, 2017, 11, 48-52.	0.8	1
12	Protective effects of taurine on doxorubicin-induced acute hepatotoxicity through suppression of oxidative stress and apoptotic responses. Anti-Cancer Drugs, 2016, 27, 17-23.	1.4	50
13	Theanine prevents doxorubicin-induced acute hepatotoxicity by reducing intrinsic apoptotic response. Food and Chemical Toxicology, 2015, 78, 147-152.	3.6	43
14	Decreased elimination clearance of midazolam by doxorubicin through reductions in the metabolic activity of hepatic CYP3A in rats. Xenobiotica, 2015, 45, 874-880.	1.1	5
15	Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol. Biopharmaceutics and Drug Disposition, 2015, 36, 174-182.	1.9	3
16	Effect of fluoxetine and pergolide on expression of nucleoside transporters and nucleicâ€related enzymes in mouse brain. Fundamental and Clinical Pharmacology, 2014, 28, 217-220.	1.9	5
17	Underestimation of rat serum vancomycin concentrations measured by an enzymeâ€multiplied immunoassay technique and the strategy for its avoidance. Drug Testing and Analysis, 2014, 6, 350-356.	2.6	4
18	Non-Destructive Evaluation Method of Pharmaceutical Tablet by Terahertz-Time-Domain Spectroscopy: Application to Sound-Alike Medicines. Journal of Infrared, Millimeter, and Terahertz Waves, 2013, 34, 566-571.	2.2	16

Hiroki Konishi

#	Article	IF	CITATIONS
19	Protection of theanine against doxorubicin-induced acute cardiac toxicity. Biomedicine and Preventive Nutrition, 2013, 3, 197-199.	0.9	6
20	Difference in nephrotoxicity of vancomycin administered once daily and twice daily in rats. Journal of Chemotherapy, 2013, 25, 273-278.	1.5	11
21	Educational Effects of Practical Training in Palliative Care for Pharmacy Students:. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2013, 39, 675-680.	0.1	2
22	Application of Terahertz Absorption Spectroscopy to Evaluation of Aging Variation of Medicine. Analytical Sciences, 2011, 27, 209-212.	1.6	14
23	Effect of blood decrease on micafungin disposition in rats. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36, 35-39.	1.6	Ο
24	Reduced elimination clearance of micafungin in rats with cholestatic hyperbilirubinemia. Fundamental and Clinical Pharmacology, 2010, 24, 457-462.	1.9	4
25	Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats. Journal of Pharmacy and Pharmacology, 2010, 55, 143-149.	2.4	13
26	Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. Journal of Pharmacy and Pharmacology, 2010, 56, 477-483.	2.4	7
27	Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. Journal of Pharmacy and Pharmacology, 2010, 56, 1259-1266.	2.4	11
28	Impact of Plasma Exchange on Pharmacokinetic Disposition of Micafungin. Therapeutic Apheresis and Dialysis, 2010, 14, 358-363.	0.9	7
29	Reduction of Opioid Side Effects by Prophylactic Measures of Palliative Care Team May Result in Improved Quality of Life. Journal of Palliative Medicine, 2010, 13, 401-406.	1.1	16
30	Change in blood tacrolimus concentration by fluctuation of renal function in a bone marrow transplant patient. European Journal of Drug Metabolism and Pharmacokinetics, 2009, 34, 201-204.	1.6	2
31	Long-Term Glycemic Control after a One Week Hospital Education Program for Inpatients with Type 2 Diabetes. Journal of Pharmacy Technology, 2007, 23, 263-269.	1.0	2
32	Failure of Pain Control Using Transdermal Fentanyl During Rifampicin Treatment. Journal of Pain and Symptom Management, 2007, 33, 5-6.	1.2	14
33	Pharmacokinetic Behavior of Micafungin in Rats with Carbon Tetrachloride-Induced Acute Hepatic Failure. Biological and Pharmaceutical Bulletin, 2005, 28, 556-559.	1.4	14
34	Note in statistical treatment of medical and pharmaceutical data. Journal of Bioscience and Bioengineering, 2005, 100, 116-118.	2.2	0
35	Withdrawal symptom after discontinuation of transdermal fentanyl at a daily dose of 0.6 mg. International Journal of Clinical Pharmacy, 2005, 27, 13-15.	1.4	6
36	Pain Recurrence on the Third Day after Application of a Transdermal Fentanyl Patch. International Journal of Clinical Pharmacy, 2005, 27, 353-353.	1.4	4

Hiroki Konishi

#	Article	IF	CITATIONS
37	Urinary 6β-hydroxycortisol/17-hydroxycorticosteroids ratio as a measure of hepatic CYP3A4 capacity after enzyme induction. Annals of Clinical Biochemistry, 2004, 41, 335-337.	1.6	12
38	Pharmacokinetic Analysis of Theophylline to Assess Noncompliance in Therapy. Annals of Pharmacotherapy, 2002, 36, 835-838.	1.9	0
39	Probable Metabolic Interaction of Doxifluridine with Phenytoin. Annals of Pharmacotherapy, 2002, 36, 831-834.	1.9	20
40	Fluctuation in Therapeutic Control Associated with Interchange of Prednisolone Tablet Formulations: Assessment of Bioequivalence by Dissolution Test. Yakugaku Zasshi, 2002, 122, 813-817.	0.2	7
41	Moricizine, an Antiarrhythmic Agent, as a Potent Inhibitor of Hepatic Microsomal CYP1A. Pharmacology, 2002, 66, 190-198.	2.2	3
42	Interference by danazol with the Porter-Silber method for determination of urinary 17-hydroxycorticosteroids. Annals of Clinical Biochemistry, 2001, 38, 277-279.	1.6	5
43	Assessment of Comprehension Levels of Inpatients with Diabetes Mellitus. Educational Significance for Enhancement of Therapeutic Outcome Iryo Yakugaku (Japanese Journal of Pharmaceutical Health) Tj ETQq1	1 0.7 843	14
44	Involvement of CYP2E in 8-Hydroxylation of Theophylline in Mouse Hepatic Microsomes-Difference from Its N-Demethylations Biological and Pharmaceutical Bulletin, 1996, 19, 593-598.	1.4	5
45	Multiplicity of Cytochrome P-450 Species Involved in Theophylline Metabolism in Mouse Hepatic Microsomes Biological and Pharmaceutical Bulletin, 1995, 18, 576-580.	1.4	10
46	Measurement of theophylline metabolites produced by reaction with hepatic microsome by high performance liquid chromatography following solid phase extraction. Biomedical Chromatography, 1994, 8, 189-192.	1.7	11
47	Fluconazole: A Potent Inhibitor of Cytochrome P-450-Dependent Drug-Metabolism in Mice and Humans in Vivo. Comparative Study with Ketoconazole Chemical and Pharmaceutical Bulletin, 1992, 40, 1247-1251.	1.3	35
48	Ozagrel hydrochloride monohydrate, a thromboxane synthase inhibitor, and its metabolites as inhibitors of hepatic microsomal drug metabolism Chemical and Pharmaceutical Bulletin, 1989, 37, 3351-3354.	1.3	6
49	Inducing effect of carbamazepine on oxidative drug-metabolizing enzymes in children Japanese Journal of Clinical Pharmacology and Therapeutics, 1988, 19, 431-435.	0.1	3
50	A comparison of the inhibitory effects of roxatidine acetate hydrochloride and cimetidine on cytochrome P-450-mediated drug-metabolism in mouse hepatic microsomes and in man in vivo Journal of Pharmacobio-dynamics, 1987, 10, 287-295.	0.5	20
51	Comparison of the inhibitory effects of famotidine and cimetidine on hepatic oxidative metabolism of cortisol in humans Japanese Journal of Clinical Pharmacology and Therapeutics, 1987, 18, 509-513.	0.1	11
52	High-performance liquid chromatographic determination of 6.BETAhydroxycortisol in urine Chemical and Pharmaceutical Bulletin, 1986, 34, 2522-2527.	1.3	28